Navigation Links
Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference

RICHMOND, VA., July 9 /CNW/ - Insmed Inc. (NASDAQ:INSM), a biopharmaceutical company focused on the development and approval of drugs for the treatment of metabolic diseases with unmet medical needs, today announced that it will present at this week's C.E. Unterberg, Towbin (CEUT) Emerging Growth Opportunities Conference in New York City.

The conference, to be held at the Mandarin Oriental Hotel in New York City, will run from Tuesday, July 10th through Thursday, July 12th. Dr. Geoffrey Allan, Ph.D., Insmed's President and CEO, will make the presentation on Thursday, July 12th at 8:30 a.m.; the Company will also hold one-on-one meetings with investment firm representatives. A live video Webcast of the presentation will be available at the investor relations section of Insmed's website,

Dr. Allan said, "We are especially pleased to be participating in this year's CEUT conference, because it gives us an ideal forum to present our dual strategy growth plan, based on our approved proprietary protein platform and the development and manufacture of follow-on biologics, to a crucial audience of investment managers and analysts. Insmed has a very timely story to tell, and we are glad to get this opportunity to tell it at such a high-visibility event."

About Insmed

Insmed is a biopharmaceutical company focused on the development and approval of drugs for the treatment of metabolic diseases with unmet medical needs. For more information please visit

Forward Looking Statements: This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in th is release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, the Company may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than the Company, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

For further information: Investor Relations International Haris Tajyar, 818-382-9702


Related medicine technology :

1. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
2. Insmed Announces Promising Results From IPLEX Phase II Myotonic Muscular Dystrophy Clinical Study
3. Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
4. The Past, Present and Future of HLA Typing
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
10. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
11. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:11/24/2015)... , Nueva York , 24 ... Devices (ABD), fabricante del Avery Breathing Pacemaker System, ... Jonzon , MD; Ph.D. como consultor clínico. ...   --> Foto - ... El doctor Jonzon es un fisiólogo y ...
(Date:11/24/2015)... India , November 24, 2015 ... market research report "Spine Biologics Market by Product Type (Bone ... (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), End ... MarketsandMarkets, the global market was valued at $1.90 Billion in ... at a CAGR of 4.4% during the forecast period of ...
(Date:11/24/2015)... , Nov. 24, 2015   HeartWare International, ... of less-invasive, miniaturized circulatory support technologies that are revolutionizing ... President and Chief Executive Officer Doug Godshall ... th Annual Healthcare Conference on December 1, 2015 ... December 1-2 in New York . ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, AZ) - ... surgeon specializing in both surgical and non-surgical treatments, announced the expansion of his ... Facial Plastic Surgery. , Highly trained and nationally recognized for his natural ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw YMCA’s student-produced musical ... its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions for this ... Brillianteen has been a treasured tradition for numerous families in the Evanston community. ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... “While riding ... an inventor, from Bronx, N.Y. “I thought there had to be a convenient and ... the PROTECTOR. , The PROTECTOR enables disabled individuals to safely travel during cold or ...
(Date:11/25/2015)... ST. LOUIS, Missouri (PRWEB) , ... November 25, ... ... with Project HEAL, will provide scholarships for people struggling with eating disorders as ... Proceeds from the second annual event, held at Fox Run Golf Club ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... I found that regular bras were incredibly uncomfortable," said an inventor from Bronx, ... bra." , She developed the patent-pending RECOVERY BRA for added comfort and support. ...
Breaking Medicine News(10 mins):